|
|
|
|
|
|
Sponsored by: |
Procter and Gamble |
Information provided by: | Procter and Gamble |
ClinicalTrials.gov Identifier: | NCT00384046 |
The purpose of this study is to examine whether the transdermal testosterone system (TTS) is effective and safe in the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women who are on transdermal estrogen.
Condition | Intervention | Phase |
Hypoactive Sexual Desire Disorder |
Drug: Testosterone Drug: Placebo |
Phase III |
MedlinePlus related topics: | Menopause |
Drug Information available for: | Testosterone Methyltestosterone Oxymesterone Testosterone enanthate Testosterone Propionate Testosterone undecanoate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | 24-Week Study to Evaluate the Efficacy/Safety of Transdermal Testosterone in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder Receiving Systemic Transdermal Estrogen Therapy. |
Estimated Enrollment: | 300 |
Study Start Date: | November 2006 |
Estimated Study Completion Date: | March 2008 |
Estimated Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
300mcg/day testosterone
|
Drug: Testosterone
patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
|
2: Placebo Comparator
Placebo arm
|
Drug: Placebo
patch, placebo, patch changed every 3-4 days, 24 weeks
|
This is a randomised, double-blind, placebo-controlled, parallel-group, multicentre, 24 week study to be conducted in approximately 300 patients at approximately 14 clinical sites in the UK, 6 sites in Australia, 5 sites in Germany, and 2 sites in Canada. Women will be randomised 1:1 to receive 300 mcg/day TTS or placebo for a 24 week period. Consistent with previous phase III studies, efficacy will be assessed over 24 weeks using the Sexual Activity Log (SAL), and at 12 and 24 weeks using the Profile of Female Sexual Function (PFSF) and Personal Distress Scale (PDS). Safety will be assessed over the entire 24 weeks. Hormone data (free and total testosterone, total estradiol, and sex hormone binding globulin) will be collected at Weeks -4 and 24. The total duration of treatment for each patient is 24 weeks.
Ages Eligible for Study: | 40 Years to 70 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Show 31 Study Locations |
Procter and Gamble |
Study Director: | Imran A Lodhi, MD | Procter and Gamble |
Responsible Party: | Procter and Gamble Pharmaceuticals ( Imron Lodhi, MD ) |
Study ID Numbers: | 2005108 |
First Received: | October 3, 2006 |
Last Updated: | February 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00384046 |
Health Authority: | Canada: Health Canada; United States: Food and Drug Administration |
|
|
|
|